SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)
$ARCT
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/28/2025 | $32.00 | Sector Outperform | Scotiabank |
1/28/2025 | $41.00 | Buy | BTIG Research |
8/12/2024 | $70.00 | Outperform | Leerink Partners |
12/13/2023 | $90.00 | Buy | Canaccord Genuity |
7/24/2023 | $71.00 | Outperform | William Blair |
5/11/2023 | $19.00 → $51.00 | Neutral → Buy | H.C. Wainwright |
11/14/2022 | $35.00 | Overweight | Wells Fargo |
11/10/2022 | $18.00 | Neutral → Underperform | Robert W. Baird |
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)